Results 81 to 90 of about 117,976 (202)

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Therapeutics and Clinical Risk Management, 2022
Tanzila S Razzaki,* Alyson Weiner,* Alpana P Shukla Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism Weill Cornell Medicine, New York, NY, USA*These authors contributed equally to this ...
Razzaki TS, Weiner A, Shukla AP
doaj  

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. [PDF]

, 2012
Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neoplasia (PanIN). Treatment with the glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks induced the expansion of PDGs with mucinous metaplasia and
Butler, Peter C, Dawson, David, Dry, Sarah M, Gier, Belinda, Kirakossian, David, Matveyenko, Aleksey V   +5 more
core   +1 more source

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus

Терапевтический архив, 2014
AIM. To study the secretion of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 2 (GLP-2) in response to a carbohydrate load in people with risk factors for type 2 diabetes mellitus (DM2) in ...
E A Shestakova, A V Il'in, M V Shestakova, I I Dedov   +3 more
doaj  

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2 [PDF]

Current Opinion in Lipidology, 2018
Purpose of review The intestine is highly efficient at absorbing and packaging dietary lipids onto the structural protein apoB48 for distribution throughout the body. Here, we summarize recent advances into understanding the physiological and pharmacological actions of the proglucagon-derived peptides: glucagon like peptide 1 ...
openaire   +2 more sources

Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport

Molecular Metabolism, 2017
Objective: Glucagon-like peptide-2 (GLP-2) is co-secreted with GLP-1 from gut endocrine cells, and both peptides act as growth factors to expand the surface area of the mucosal epithelium.
Jennifer Lee, Jacqueline Koehler, Bernardo Yusta, Jasmine Bahrami, Dianne Matthews, Mahroukh Rafii, Paul B. Pencharz, Daniel J. Drucker   +7 more
doaj   +1 more source

Immunological characterization of chromogranins A and B and secretogranin II in the bovine pancreatic islet [PDF]

, 1987
Antisera against chromogranin A and B and secretogranin II were used for analysing the bovine pancreas by immunoblotting and immunohistochemistry. All three antigens were found in extracts of fetal pancreas by one dimensional immunoblotting. A comparison
A Iacangelo, AD Smith, BS Wilson, C Hagn, D Grube, D Grube, D Grube, DT O'Connor, DT O'Connor, DV Cohn, E El-Nady, FU Reiffen, FU Reiffen, G Falkensammer, G Falkensammer, G Rindi, H Blaschko, H Lassmann, H Winkler, HD Mayor, IM Varndell, JA Nolan, JC Hutton, K Tatemoto, KB Helle, KB Helle, L Kilpatrick, LA Sternberger, LE Eiden, M Ehrhart, M Ravazzola, P Rosa, PH O'Farell, R Fischer-Colbrie, R Fischer-Colbrie, R Fischer-Colbrie, R Fischer-Colbrie, RV Floyd, S Bonner-Weir, S Lenzen, UK Laemmli, UM Benedum, WB Huttner, WJ Smith, WN Burnette   +44 more
core   +1 more source

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes

Journal of Diabetes Investigation, 2023
Young Min Cho
doaj   +1 more source

Diffuse Podocytopathy Associated With Semaglutide

Annals of Internal Medicine: Clinical Cases
We present 3 cases of biopsy-proven minimal change disease occurring in close temporal association with semaglutide (glucagon-like peptide 1 receptor agonists) exposure.
Rose Mary Attieh, Grant Kirby, Yang Yihe, Serena Bagnasco, Andrew A. Moses, Mahmoud Abdelaziz, Rimda Wanchoo, Samir Gautam, Astrid Weins, Kenar D. Jhaveri   +9 more
doaj   +1 more source

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +1 more source

The glucagon-like Peptide-2

, 2011
Multiple peptide hormones produced within the gastrointestinal system act also in the central nervous system and aid in the regulation of energy homeostasis and metabolism. The list of these peptides is progressively increasing and includes glucagon-like peptide 2 (GLP-2) as an anorexigenic factor.
openaire   +2 more sources